Automated CRISPR-Cas9 Gene Editing Ribonucleoprotein (RNP) Foundry Cap Rate 2026

Underwrite GMP Class A/B continuous synthetic single guide RNA (sgRNA) and recombinant Cas9/Cas12 endonuclease ribonucleoprotein (RNP) complex assembly suites, $500/sqft base lease rates, and exit cap rates.

Underwriting Assumptions

CRISPR RNP Cleanroom Footprint (sqft)

NNN Base Lease Rate ($/sqft/yr)

Turnkey GMP CRISPR Facility Acquisition ($)

Target Exit Capitalization Rate (%)

Projected Economics

Net Operating Income (NOI)

Going-In Capitalization Rate

Stabilized Institutional Valuation